Independent Contract Sales Representative (1099) – Hawaii

AVITA Medical is a therapeutic acute wound care company focused on advancing skin restoration through innovative technologies that support improved healing, reduced patient burden, and more efficient treatment pathways across complex wounds.

• RECELL® Spray-On Skin™ Cells – An FDA-approved autologous cell harvesting technology that uses a patient’s own skin cells for the treatment of thermal burns and full-thickness skin defects.
• Cohealyx™ Collagen Dermal Matrix – A collagen-based dermal matrix designed to support tissue integration, revascularization, and readiness for definitive closure in full-thickness wounds.
• PermeaDerm® Biosynthetic Wound Matrix – A transparent, conformable wound matrix used for partial- and full-thickness wounds, burns, donor sites, and surgical wounds.

Together, the portfolio gives surgeons and care teams complementary solutions across the acute wound healing continuum—from temporary coverage and wound bed preparation to definitive closure.

AVITA Medical is looking for an established independent medical device representative in Hawaii who already has strong access across hospital-based surgical specialties and understands how to drive adoption in the operating room, burn, trauma, plastics, and advanced wound care settings.

This is a portfolio expansion opportunity for a proven 1099 representative who is already calling on Hawaii’s acute care hospitals, surgeons, OR teams, burn programs, trauma services, wound care teams, and value analysis stakeholders—and who wants to add a differentiated regenerative medicine and acute wound care portfolio to an existing book of business.

The Opportunity

Hawaii is a relationship-driven hospital market. We are seeking a representative who knows the territory, understands complex hospital sales cycles, and can credibly engage surgeons, OR leadership, burn and trauma stakeholders, wound care teams, supply chain, and value analysis committees.

The right partner will be comfortable building clinical confidence, supporting procedures, advancing VAC and formulary discussions, and creating pull-through once products are approved and adopted.